Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The p53 protein, encoded by the frequently mutated TP53 gene, is a crucial tumor suppressor.
• Mutations in p53 disrupt tumor suppression and promote cancer progression, metastasis, and chemoresistance.
• Mutant p53 neoantigens can trigger anti-tumor T cell responses, making them targets for immunotherapy.

Purpose of the Study:

• To review the potential of p53 antigens as targets in cancer immunotherapy.
• To explore novel approaches like T cell receptor mimic monoclonal antibodies for p53-targeted therapies.

Main Methods:

• Literature review of p53 mutations in cancer.
• Analysis of immunogenic properties of mutant p53.
• Discussion of T cell receptor mimic monoclonal antibody applications.

Main Results:

• TP53 is the most frequently mutated gene in human cancers.
• Mutant p53 gains oncogenic functions and loses tumor suppressive roles.
• Mutant p53 is immunogenic, eliciting T cell responses.

Conclusions:

• p53 is a promising, yet challenging, target for cancer therapy.
• Targeting mutant p53 via immunotherapy, particularly with TCRm mAbs, offers a novel therapeutic strategy.